Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice

Gene Therapy

Volumn 22, Issue 6, 2015, Pages 439-448

  Pi, Y ^a   Zhang, X ^a   Shao, Z ^a   Zhao, F ^a   Hu, X ^a   Ao, Y ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; COLLAGEN TYPE 10; COLLAGENASE 3; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, MOUSE; MESSENGER RNA; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL HOMING; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOLOGY; IN VITRO STUDY; KNEE OSTEOARTHRITIS; MALE; MORPHOLOGY; MORPHOMETRICS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SYNOVITIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; GENE VECTOR; INFLAMMATION; KNEE; METABOLISM; OSTEOARTHRITIS; PATHOLOGY; SYNOVIUM;

MUS;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARTILAGE, ARTICULAR; CHONDROCYTES; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; KNEE JOINT; MICE; NANOPARTICLES; OSTEOARTHRITIS; PEPTIDES; RNA, MESSENGER; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE;

EID: 84930483467     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.16     Document Type: Article

References (50)

1. Newman AP. Articular cartilage repair. Am J Sports Med 1998; 26: 309-324.
2. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta 2012; 1824: 133-145.
3. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009; 15: 1072-1076.
4. Aigner T, McKenna L. Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci 2002; 59: 5-18.
5. Miyaki S, Nakasa T, Otsuki S, Grogan SP, Higashiyama R, Inoue A et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Athritis Rheum 2009; 60: 2723-2730.
6. Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Athritis Rheum 2010; 62: 1361-1371.
7. Zwerina J, Redlich K, Polzer K, Joosten L, Krönke G, Distler J et al. TNF-induced structural joint damage is mediated by IL-1. PNAS 2007; 104: 11742-11747.
8. Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60: 2008-2018.
9. Chia SL, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Athritis Rheum 2009; 60: 2019-2027.
10. Flemming A. Target identification: HIF2alpha central player in osteoarthritis. Nat Rev Drug Discov 2010; 9: 517.
11. Husa M, Liu-Bryan R, Terkeltaub R. Shifting HIFs in osteoarthritis. Nat Med 2010; 16: 641-644.
12. Ryu JH, Shin Y, Huh YH, Yang S, Chun CH, Chun JS. Hypoxia-inducible factor-2 regulates Fas-mediated chondrocyte apoptosis during osteoarthritic cartilage destruction. Cell Death Differ 2012; 19: 440-450.
13. Murphy CL. HIF-2alpha - a mediator of osteoarthritis? Cell Res 2010; 20: 977-979.
14. Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat Med 2010; 16: 678-686.
15. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, Min BH et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010; 16: 687-693.
16. Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther 2004; 11: 379-389.
17. Martinek V, Ueblacker P, Imhoff AB. Current concepts of gene therapy and cartilage repair. J Bone Joint Surg Br 2003; 85: 782-788.
18. Chen LX, Lin L, Wang HJ, Wei XL, Fu X, Zhang JY et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008; 16: 174-184.
19. Wang CR, Shiau AL, Chen SY, Cheng ZS, Li YT, Lee CH et al. Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther 2010; 17: 1225-1233.
20. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009; 17: 162-168.
21. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005; 6: 299-310.
22. Jabr-Milane L, van Vlerken L, Devalapally H, Shenoy D, Komareddy S, Bhavsar M et al. Multi-functional nanocarriers for targeted delivery of drugs and genes. J Control Release 2008; 130: 121-128.
23. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 1647-1652.
24. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006; 114: 100-109.
25. Pi Y, Zhang X, Shi J, Zhu J, Chen W, Zhang C et al. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials 2011; 32: 6324-6332.
26. Henson FM, Vincent TA. Alterations in the vimentin cytoskeleton in response to single impact load in an in vitro model of cartilage damage in the rat. BMC Musculoskelet Disord 2008; 9: 94.
27. Laverty S, Girard CA, Williams JM, Hunziker EB, Pritzker KP. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 2010; 18(Suppl 3): S53-S65.
28. Pawlus MR, Hu CJ. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal 2013; 25: 1895-1903.
29. Boissier MC, Bessis N. Risks and benefits of articular gene therapy. Joint Bone Spine 2003; 70: 486-488.
30. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 2000; 7: 1930-1939.
31. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11(Suppl 1): S10-S17.
32. Mukherjee J. Nanosize drug delivery system. Curr Pharm Biotechnol 2014; 14: 1221.
33. Amar-Lewis E, Azagury A, Chintakunta R, Goldbart R, Traitel T, Prestwood J et al. Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing. J Control Release. 2014; 185: 11.
34. Fixler D, Zalevsky Z. In vivo tumor detection using polarization and wavelength reflection characteristics of gold nanorods. Nano Lett 2013; 13: 4.
35. Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, Kisin-Finfer E, Redy O, Srinivasan S et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014; 6: 3742-3752.
36. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9: 615-627.
37. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010; 5: 143-159.
38. Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Arntz OJ et al. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis. Ann Rheum Dis 2011; 70: 2167-2175.
39. Saidenberg-Kermanac'h N, Bessis N, Deleuze V, Bloquel C, Bureau M, Scherman D et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003; 5: 164-171.
40. Loboda A, Jozkowicz A, Dulak J. HIF-1 versus HIF-2-Is one more important than the other? Vasc Pharmacol 2012; 56: 245-251.
41. Pawlus MR, Wang L, Ware K, Hu CJ. Upstream stimulatory factor 2 and hypoxiainducible factor 2 (HIF2) cooperatively activate HIF2 target genes during hypoxia. Mol Cell Biol 2012; 32: 4595-4610.
42. Pawlus MR, Wang L, Murakami A, Dai G, Hu CJ. STAT3 or USF2 contributes to HIF target gene specificity. PLOS One 2013; 8: e72358.
43. Sena JA, Wang L, Hu CJ. BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxiainducible transcription factor target genes. Mol Cell Biol 2013; 33: 3849-3863.
44. Shay JE, Celeste Simon M. Hypoxia-inducible factors: Crosstalk between inflammation and metabolism. Semin Cell Dev Biol 2012; 23: 389-394.
45. Zhao X, Yue Y, Cheng W, Li J, Hu Y, qin L et al. Hypoxia-inducible factor: a potential therapeutic target for rheumatoid arthritis. Curr Drug Targets 2013; 14: 7.
46. Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 2012; 7: 389-393.
47. Alexis F, Zeng J, Shu W. PEI nanoparticles for targeted gene delivery. In: Friedmann T, Rossi J eds. Gene transfer: delivery and expression of DNA and RNA a laboratory manual. Cold Spring Harbor Laboratory Press: New York pp 473-477, 2007.
48. Harrison PE, Ashton IK, Johnson WE, Turner SL, Richardson JB, Ashton BA. The in vitro growth of human chondrocytes. Cell Tissue Bank 2000; 1: 255-260.
49. Caramés B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum 2010; 62: 791-801.
50. Kozawa E, Nishida Y, Cheng XW, Urakawa H, Arai E, Futamura N et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. Arthritis Rheum 2012; 64: 454-464.